Duality Biotherapeutics, Inc. (“DualityBio”) reported two capital-structure transactions on 3 November 2026 that marginally reduced its outstanding share base and lifted treasury share holdings.
Transaction Highlights • Share repurchase: DualityBio bought back 15,000 ordinary shares on the Hong Kong Stock Exchange at prices between HKD 99.40 and HKD 101.20, for a volume-weighted average cost of HKD 100.39 per share. The cash outlay totalled HKD 1.51 million. The shares were retained as treasury stock. • Option exercise: 9,300 new shares were issued upon the exercise of options granted under the company’s Pre-IPO Equity Incentive Plan (adopted 28 Feb 2021; amended 25 Jun 2023) at HKD 9.81 per share.
Impact on Share Capital • Opening balance (2 Nov 2026): 91.06 million issued shares (excluding 0.85 million treasury shares). • Net change on 3 Nov 2026: −15,000 shares repurchased (-0.016 %) and +9,300 shares issued, resulting in a net reduction of 5,700 shares. • Closing balance: 91.05 million issued shares (excluding 0.86 million treasury shares); total issued shares, including treasury shares, stood at 91.91 million.
Treasury Share Position • Treasury shares rose to 862,700 after the buyback, up from 847,700 previously. • Repurchased shares are held as treasury stock; none have been cancelled as of the reporting date.
Repurchase Mandate Utilisation • The 15,000-share repurchase forms part of a mandate approved on 26 Jun 2026, which authorises buybacks of up to 9.06 million shares. • Cumulative purchases under this mandate now total 536,400 shares, equivalent to 0.59 % of the issuer’s share count at the mandate date. • Following the latest transaction, DualityBio is subject to a 30-day moratorium—until 2 Dec 2026—on issuing new shares or selling treasury shares without Exchange approval.
Governance and Compliance The board confirmed all transactions were duly authorised and executed in accordance with Hong Kong listing rules, corporate laws, and the company’s repurchase mandate.
Financial Context While the repurchase represents a modest capital deployment of HKD 1.51 million and trims the free-float by 0.006 % on a net basis, the simultaneous option exercise modestly offsets the reduction. The company’s disciplined use of its approved buyback capacity leaves approximately 8.52 million shares (94.3 % of mandate) still available for future repurchases.
Comments